Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 2Multiple Myeloma 2Solid Tumors 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms, Plasma Cell 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

fludarabine phosphate 38Cyclophosphamide 37Peripheral Blood Stem Cell Transplantation 32Busulfan 28Tacrolimus 26Whole-Body Irradiation 20Mycophenolic Acid 19Methotrexate 17Antilymphocyte Serum 17ruxolitinib 16fludarabine 14Filgrastim 13Cyclosporine 12Melphalan 11Radiotherapy 9Etoposide 9thymoglobulin 8Psychiatric Rehabilitation 8Prednisone 8Methylprednisolone 8Cytarabine 6Cord Blood Stem Cell Transplantation 6Thiotepa 5Sirolimus 5Imatinib Mesylate 5Flow Cytometry 5Azacitidine 5Alemtuzumab 5sargramostim 4merphos 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Primary Myelofibrosis × LCL161 × Clear all
NCT02098161 2023-06-06

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 11 charts
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡